Thermo Fisher Scientific has launched the new Molecular Microscope Diagnostic System for Lung (MMDx Lung), a new test to assist in evaluating lung transplant biopsies, which could lead to the detection of rejection and injury in patients.
The company said that current diagnostic practices face challenges, with research indicating that there is only an 18% consensus among pathologists when diagnosing acute rejection from lung biopsy samples.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
To address this, MMDx Lung employs machine learning (ML) to analyse the data of gene expression from lung biopsies.
By comparing each sample against more than 896 lung biopsy reference sets, the system calculates the likelihood of rejection and gives molecular scores that reflect injury and graft dysfunction, as well as rejection.
This approach is expected to support pathologists in making evaluations, potentially leading to informed treatment decisions for lung transplant recipients.
Kashi Clinical Laboratories developed and validated MMDx Lung, which is currently utilised for clinical use in a Clinical Laboratory Improvement Amendments (CLIA)-certified lab.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThermo Fisher noted that the test has not received clearance or approval by the US Food and Drug Administration or obtained a CE mark in the EU as an in vitro diagnostic test.
The company has also highlighted the ongoing challenges faced by lung transplant recipients, who experience higher rejection rates compared to other solid organ transplant patients.
Thermo Fisher Scientific Transplant Diagnostics president Tina Liedtky said: “The launch of MMDx Lung enhances our comprehensive portfolio of post-transplant monitoring solutions and reflects our ongoing commitment to helping our customers personalise patient care and improve outcomes throughout the transplant journey.”
MMDx and Molecular Microscope are Transcriptome Sciences’ registered trademarks.
In August 2025, Thermo Fisher teamed up with Taiwanese life science company Syncell to integrate the latter’s Microscoop Mint technology into its Orbitrap Astral mass spectrometer.
